Head to Delki Dozzi Track that Saturday to raise awareness of the disease and raise funds for research and services ...

Community members are invited to attend the Rockin’ for Research ALS Benefit Concert on Saturday, June 13, to help raise ...

PRESS RELEASEAB SCIENCE IS INVITED TO PRESENT AT THE 2026 ENCALS ANNUAL MEETING THE SURVIVAL DATA FROM MASITINIB CLINICAL PROGRAM IN AMYOTROPHIC ...

The statistical methods scientists use to analyze outcomes from clinical trials in amyotrophic lateral sclerosis (ALS) vary widely, and these differences may make some trials prone to generating ...

Advocates and healthcare stakeholders are using ALS Awareness Month in June to call for greater support, earlier diagnosis ...

The number of patients living with neurodegenerative diseases that affect movement is rising steadily. Yet a large-scale ...

Participants who finish the initial stage continue their regimen; placebo recipients are re-randomised to two COYA 302 dosing ...

The muscle nicotinic acetylcholine receptor (AChR) is the key mediator of neuromuscular signal transmission and is essential for all voluntary movement in our body. In this study, we present ...

An expert interview explores the scientific necessity of patient experience data in amyotrophic lateral sclerosis drug ...

This story was excerpted from Keegan Matheson's Blue Jays Beat newsletter. To read the full newsletter, click here. And ...

Once issued, this patent is expected to expire no earlier than September 2042. The allowed claims cover not only the combination of ibudilast with multiple anti-PD-1 antibodies, but also a broad range ...

UCSD study says the therapy increased expression of a neuroprotective protein to help preserve brain functions, despite the ...